A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors

NCT02573259 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

147

Enrollment

INDUSTRY

Sponsor class

Conditions

Part 1
MELANOMA
SCCHN
OVCA
SARCOMA
OTHER SOLID TUMORS
Part 1 and 2
NSCLC
UROTHELIAL CARCINOMA

Interventions

DRUG: PF-06801591
DRUG: PF-06801591

Sponsor

Pfizer